EKSO — Ekso Bionics Holdings Share Price
0.000.00%
Last trade - 00:00- $19.17m
- $16.22m
- $18.28m
- 33
- 47
- 41
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.4 | ||
| Price to Tang. Book | 2.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.81% | ||
| Return on Equity | -80.59% | ||
| Operating Margin | -78.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.92 | 8.88 | 11.25 | 12.91 | 18.28 | 21.55 | 27.81 | 10.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
Directors
- Steven Sherman CHM (76)
- Scott Davis PRE (52)
- John Glenn CFO (59)
- Jason Jones VPR (49)
- William Shaw OTH (47)
- Stanley Stern LED (63)
- Corinna Lathan DRC (54)
- Mary Cloyd IND (66)
- Charles Li IND (35)
- Rhonda Wallen IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 30th, 2012
- Public Since
- April 10th, 2013
- No. of Shareholders
- 175
- No. of Employees
- 70
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,174,426
- Address
- 101 GLACIER POINT, SUITE A, SAN RAFAEL, 94901
- Web
- https://ir.eksobionics.com/
- Phone
- +1 5109841761
- Contact
- David Carey
- Auditors
- WithumSmith Brown PC
Upcoming Events for EKSO
Q3 2024 Ekso Bionics Holdings Inc Earnings Release
Similar to EKSO
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
FAQ
What is the Ekso Bionics Holdings share price?
As of Today at 20:26 UTC, shares in Ekso Bionics Holdings are trading at $1.08. This share price information is delayed by 15 minutes.
How has the Ekso Bionics Holdings share price performed this year?
Shares in Ekso Bionics Holdings last closed at $1.08 and the price had moved by -23.4% over the past 365 days. In terms of relative price strength the Ekso Bionics Holdings share price has underperformed the S&P500 Index by -39.05% over the past year.
What are the analyst and broker recommendations for Ekso Bionics Holdings?
The overall consensus recommendation for Ekso Bionics Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ekso Bionics Holdings dividend yield?
Ekso Bionics Holdings does not currently pay a dividend.
Does Ekso Bionics Holdings pay a dividend?
Ekso Bionics Holdings does not currently pay a dividend.
When does Ekso Bionics Holdings next pay dividends?
Ekso Bionics Holdings does not currently pay a dividend.
How do I buy Ekso Bionics Holdings shares?
To buy shares in Ekso Bionics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ekso Bionics Holdings?
As of the previous close price of $1.08, shares in Ekso Bionics Holdings had a market capitalisation of $19.63m.
Where are Ekso Bionics Holdings shares listed?
Here are the trading details for Ekso Bionics Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EKSO
What kind of share is Ekso Bionics Holdings?
Based on an overall assessment of its quality, value and momentum Ekso Bionics Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ekso Bionics Holdings share price forecast for 2024?
The analyst consensus target price for shares in Ekso Bionics Holdings is $10.00. That is 825.93% above the last closing price of $1.08.
Analysts covering Ekso Bionics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.43 for the next financial year.
What is the trend in the Ekso Bionics Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ekso Bionics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -44.16%.
As of the last closing price of $1.08, shares in Ekso Bionics Holdings were trading -24.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ekso Bionics Holdings PE Ratio?
The Ekso Bionics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ekso Bionics Holdings?
Ekso Bionics Holdings' management team is headed by:
- Steven Sherman - CHM
- Scott Davis - PRE
- John Glenn - CFO
- Jason Jones - VPR
- William Shaw - OTH
- Stanley Stern - LED
- Corinna Lathan - DRC
- Mary Cloyd - IND
- Charles Li - IND
- Rhonda Wallen - IND